NIH Reissues Parent SBIR PA-27-100 With $3M Cap and a September 5 Deadline

Biotech and health-tech SBIR founders have a hard date to circle: NIH's reissued Parent SBIR omnibus, PA-27-100, reopens the federal government's largest small-business R&D pipeline with a September 5, 2026 first receipt date and per-award caps reaching $3 million, per the grants.gov listing.

What PA-27-100 Actually Covers

PA-27-100 is the master NIH, CDC and FDA SBIR omnibus for the FY27 application year — the parent funding opportunity that the majority of biotech, diagnostic, digital-health and medical-device small businesses file against. The full announcement, posted at grants.gov opportunity 359671, names 27 participating NIH Institutes and Centers, nine CDC centers and five FDA centers including CBER, CDER and CDRH. The R43 designation funds Phase I feasibility work; R44 covers Phase II development; Fast-Track and Direct-to-Phase II submissions are accepted under the same parent.

The "Clinical Trial Optional" framing is the most important structural change applicants should register. Under the previous generation, PHS 2024-2 split applications into PA-24-245 (Clinical Trial Not Allowed) and PA-24-246 (Clinical Trial Required). The new omnibus consolidates the two tracks and lets applicants propose — or not propose — clinical trials inside one NOFO, subject to individual IC rules. NIAMS, NIDCR, NCATS and ORIP, plus all FDA centers, still do not accept clinical-trial applications. NCI, NHLBI, NINDS, NIA, NIAID and most other high-activity ICs do.

The Reauthorization That Made the Reissue Possible

This omnibus would not exist in May without the SBIR/STTR reauthorization signed into law on April 13, 2026. The bipartisan legislation, S. 3971, extends both small-business programs through September 30, 2031, ending a roughly three-month lapse during which NIH had to early-expire its existing Notices of Funding Opportunity under NOT-OD-26-006. The April announcement from NIH's extramural office confirmed that the agency would publish new parent NOFOs as fast as policy review allowed — and PA-27-100, alongside the companion Phase IIB award PA-27-101 and the parent STTR (R41/R42), is the result.

The dollars behind the acronyms matter. NIH alone sets aside more than $1.4 billion a year for SBIR and STTR awards from its extramural research budget, and the broader SBIR/STTR system across 11 federal agencies moves more than $4 billion annually. That makes the NIH parent the single largest dollar-weighted entry point for any U.S. small business doing health-adjacent R&D — a fact founders routinely lose sight of when they chase agency-specific topic solicitations and miss the standing omnibus underneath.

Per-Award Caps, Project Periods and the 67% Rule

Headline caps in the announcement: Phase I awards run up to $400,000 under SBA's baseline guidelines, with select participating ICs authorized to exceed that ceiling and fund up to $700,000 under approved waivers. Phase II runs up to $2 million under SBA's baseline, with most high-activity ICs — NCI, NHLBI, NIAID, NIDDK among them — authorized to fund up to $2.5 million or $3 million per Phase II award. CDC and FDA components hold to SBA baseline.

Project periods are tight. Phase I is six months or less; Phase II is two years or less. Founders whose past budgeting experience is academic R01s often underestimate how compressed Phase I is — six months of work, with a real prototype or feasibility readout, on a budget that has to cover indirect costs, fringe benefits and any outsourced testing or contracted CRO work.

Indirect cost recovery deserves explicit budgeting. Established small businesses with a negotiated rate from the Office of Naval Research can recover 40 to 50 percent on top of direct costs; first-time applicants without a rate default to the de minimis 10 percent MTDC rate or a provisional rate negotiated during the award. That can be the difference between a Phase I that funds two full FTEs and one that funds one and a half — a structural reason experienced repeat applicants tend to outperform first-time filers on the same scientific idea.

The other number to memorize is the 67/50 rule: the small business must perform at least 67 percent of the research effort in Phase I and at least 50 percent in Phase II. That cap on outsourcing to academic collaborators is what makes SBIR an actual small-business program rather than a backdoor university grant, and it is the single most common cause of administrative pushback when a first-time applicant tries to budget a CRO or university subcontract above those thresholds.

Eligibility is similarly mechanical. Applicants must be U.S.-based for-profit small business concerns with no more than 500 employees including affiliates, and more than 50 percent of the equity must be owned by U.S. citizens, permanent residents, or qualifying venture-capital operating companies under the SBA's 2012 expansion. VC-majority-owned companies are eligible only at agencies that have opted in. NIH opted in — which is why a venture-backed biotech can still file under PA-27-100 even though it could not under DoD SBIR.

The Three Standard Receipt Dates

PA-27-100 follows the long-standing tri-annual NIH cycle:

• September 5, 2026 — first standard receipt date under the new omnibus
• January 5, 2027 — second cycle
• April 5, 2027 — third cycle, with the announcement expiring April 6, 2027

For founders who missed the early-expiration window late last year, September is the practical re-entry point. NIH SEED, the office that fields SBIR/STTR questions, has long advised that a competitive Phase I application takes ten to twelve weeks of focused work — which means specific aims should already be in draft form for any team targeting September 5, and a heat-check email to the relevant IC's SBIR program officer should be scheduled before mid-June.

A second-tier consideration is the companion Phase IIB Strategic Breakthrough Award, PA-27-101, which extends Phase II projects with another tranche of non-dilutive capital aimed at late-stage commercialization. Phase IIB applications can run substantially larger than the $3M Phase II cap and are the natural follow-on for any team that lands an R44 under PA-27-100 this cycle.

What the Reviewer Scoresheet Actually Weighs

NIH SBIR success rates in recent published cycles have run in the high teens to low twenties, with meaningful variance across ICs — some institutes consistently fund a larger share of submitted applications than others. Reviewers score five criteria — Significance, Investigators, Innovation, Approach and Environment — and Significance and Approach carry the most practical weight. For SBIR specifically, Significance is read as commercial significance, not just scientific impact: a strong application names the customer, the regulatory pathway and the buyer's willingness to pay. Reviewers also see the Commercialization Plan as a standalone scored section in Phase II applications, and the reauthorization's emphasis on milestone-based commercialization makes that section more load-bearing this cycle than the previous one.

What Founders Should Do Between Now and Labor Day

The mistake first-time SBIR applicants make most often is treating PA-27-100 as a single funding opportunity rather than a directory. The omnibus is an umbrella; the real decision is which of the 27 NIH ICs is the right fit for the proposed specific aims, because each IC has its own scientific priorities, its own SBIR program officer and its own waiver authority on the dollar cap. A digital-therapeutics team building a clinical-decision-support tool for opioid use disorder is going to NIDA's program officer; a structural-biology platform team is going to NIGMS; a wearable cardiac diagnostic is going to NHLBI. Each officer has a published email and posted office hours, and the cost of a 20-minute call before drafting specific aims is functionally zero relative to the cost of writing a six-week proposal to the wrong IC.

Three other practical notes. First, the SAM.gov and eRA Commons registration chain takes four to six weeks; any company that has not already registered should start that work today, not the week before submission. Second, the small-business technical and business reviewer pool was expanded under the reauthorization, with explicit language about prioritizing commercialization milestones — so a Phase I application that omits a credible commercialization plan will be penalized more sharply than under the previous cycle. Third, the data management and sharing plan requirement applies to SBIR awards too, even at Phase I; budgets should leave room for it.

For founders trying to triangulate which active SBIR solicitations beyond the parent are open right now — agency-specific topics at DoD, DOE, NSF and the rest of the 11-agency consortium — the Granted blog and the live grants index are the fastest way to scan the landscape without reading every agency portal. Search active SBIR Phase I solicitations on Granted to see what is open across the federal government this cycle, filter by agency and deadline, and start a workspace targeting the September 5 PA-27-100 receipt date.